Formic Acid

Formic Acid

SCHEMBL29015463

CNc1cnnc2cc(-c3cc(B(O)O)ccc3OC)ccc12.O=CO

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 16/20 0.36
LRRK2 Q5S007 3/20 0.36
DHFR P00374 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24252500 0.95 PDE10A (0.40) PDE10ALRRK2DHFR
SCHEMBL29015462 0.88 LRRK2 (0.35) PDE10ALRRK2DHFR
SCHEMBL26771220 0.88 PDE10A (0.40) PDE10ALRRK2DHFR
SCHEMBL30451917 0.81 PDE10A (0.42) PDE10ALRRK2DHFR
SCHEMBL24252302 0.81 PDE10A (0.42) PDE10ALRRK2DHFR
SCHEMBL30467809 0.80 PDE10A (0.46) PDE10ALRRK2DHFR
SCHEMBL24252260 0.80 PDE10A (0.46) PDE10ALRRK2DHFR
Formic Acid SCHEMBL30467650 0.79 PDE10A (0.35) PDE10ALRRK2DHFR
Formic Acid SCHEMBL25257239 0.78 DHFR (0.39) PDE10ALRRK2DHFR
Formic Acid SCHEMBL30452356 0.78 DHFR (0.39) PDE10ALRRK2DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885LRRK2 1477/4885DHFR 1380/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PDE10A 1950/4885LRRK2 1477/4885DHFR 1380/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH PDE10A 3482/4885LRRK2 3700/4885DHFR 4573/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 PDE10A 2158/4885LRRK2 2687/4885DHFR 3196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.